Literature DB >> 23294049

Mortality and recovery from refractory status epilepticus in the intensive care unit: a 7-year observational study.

Raoul Sutter1, Stephan Marsch, Peter Fuhr, Stephan Rüegg.   

Abstract

PURPOSE: Refractory status epilepticus (RSE) is a life-threatening neurologic emergency with high mortality and morbidity. The aim of this study was to identify and quantify associations between clinical characteristics of adult RSE patients and outcome.
METHODS: Comprehensive medical chart review was performed of all consecutive adult RSE patients treated on the intensive care units of an academic tertiary care center between 2005 and 2011. Demographics, RSE etiologies and duration, comorbidities, as well as outcomes were assessed. Associations between clinical characteristics and death were quantified. KEY
FINDINGS: Of 260 patients with status epilepticus, 111 developed RSE. Hypoxic encephalopathy (23%), brain tumors (14%), known and uncontrolled epilepsy (10%), and ischemic stroke (8%) were the main etiologies. During hospitalization 38% of patients died. Hypoxic encephalopathy (HE) and brain tumors were independently associated with death (relative risk [RR] 2.41, 95% confidence interval [CI] 1.40-4.12; p = 0.001 and RR 2.81, 95%CI 1.59-4.96; p < 0.0001). The estimated hazard ratio of death was 3.1 (95% CI1.6-6.0; p = 0.001) for patients with HE and 1.1 (95% CI 0.5-2.3; p = 0.745) for patients with brain tumors. RSE duration and nonconvulsive status epilepticus in coma were independently associated with death (for every hour RR 1.001; 95%CI 1.00-1.002; p = 0.011 and RR 3.62; 95%CI 1.34-9.77; p = 0.005). SIGNIFICANCE: Brain tumors and HE had high relative risks for death and were independently associated with mortality in our cohort of critically ill RSE patients. Other clinical characteristics, as well as the use of intravenous anesthetic drugs and mechanical ventilation, may not be strongly related to outcome and should therefore be used cautiously for informed decision making regarding treatment. Wiley Periodicals, Inc.
© 2013 International League Against Epilepsy.

Entities:  

Mesh:

Year:  2013        PMID: 23294049     DOI: 10.1111/epi.12064

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  35 in total

1.  Midazolam and thiopental for the treatment of refractory status epilepticus: a retrospective comparison of efficacy and safety.

Authors:  Flavio Bellante; Benjamin Legros; Chantal Depondt; Jacques Créteur; Fabio Silvio Taccone; Nicolas Gaspard
Journal:  J Neurol       Date:  2016-02-25       Impact factor: 4.849

2.  New-onset refractory status epilepticus: Etiology, clinical features, and outcome.

Authors:  Nicolas Gaspard; Brandon P Foreman; Vincent Alvarez; Christian Cabrera Kang; John C Probasco; Amy C Jongeling; Emma Meyers; Alyssa Espinera; Kevin F Haas; Sarah E Schmitt; Elizabeth E Gerard; Teneille Gofton; Peter W Kaplan; Jong W Lee; Benjamin Legros; Jerzy P Szaflarski; Brandon M Westover; Suzette M LaRoche; Lawrence J Hirsch
Journal:  Neurology       Date:  2015-08-21       Impact factor: 9.910

3.  Advances in epilepsy in 2013 for the neurohospitalist.

Authors:  Andrew Nathan Wilner
Journal:  Neurohospitalist       Date:  2014-04

4.  Anesthetics and Outcome in Status Epilepticus: A Matched Two-Center Cohort Study.

Authors:  Raoul Sutter; Gian Marco De Marchis; Saskia Semmlack; Peter Fuhr; Stephan Rüegg; Stephan Marsch; Wendy C Ziai; Peter W Kaplan
Journal:  CNS Drugs       Date:  2017-01       Impact factor: 5.749

5.  Association of seizure duration and outcome in refractory status epilepticus.

Authors:  Dominik Madžar; Anna Geyer; Ruben U Knappe; Stephanie Gollwitzer; Joji B Kuramatsu; Stefan T Gerner; Hajo M Hamer; Hagen B Huttner
Journal:  J Neurol       Date:  2016-01-02       Impact factor: 4.849

6.  The effect of delayed anti-NMDAR encephalitis recognition on disease outcome.

Authors:  Vlatko Sulentic; Zeljka Petelin Gadze; Filip Derke; Marija Santini; Danira Bazadona; Sibila Nankovic
Journal:  J Neurovirol       Date:  2018-05-21       Impact factor: 2.643

7.  Therapeutic coma for status epilepticus: Differing practices in a prospective multicenter study.

Authors:  Vincent Alvarez; Jong Woo Lee; M Brandon Westover; Frank W Drislane; Jan Novy; Mohamed Faouzi; Nicola A Marchi; Barbara A Dworetzky; Andrea O Rossetti
Journal:  Neurology       Date:  2016-09-24       Impact factor: 9.910

8.  Safety and efficacy of intravenous lacosamide for adjunctive treatment of refractory status epilepticus: a comparative cohort study.

Authors:  Raoul Sutter; Stephan Marsch; Stephan Rüegg
Journal:  CNS Drugs       Date:  2013-04       Impact factor: 5.749

Review 9.  Nonconvulsive status epilepticus in adults - insights into the invisible.

Authors:  Raoul Sutter; Saskia Semmlack; Peter W Kaplan
Journal:  Nat Rev Neurol       Date:  2016-04-11       Impact factor: 42.937

Review 10.  Outcome predictors for status epilepticus--what really counts.

Authors:  Raoul Sutter; Peter W Kaplan; Stephan Rüegg
Journal:  Nat Rev Neurol       Date:  2013-08-06       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.